---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-076018"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:51:52.167736+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma reports Q2 2025 results with 103% asset growth and $350K licensing revenue

## Summary
- Total consolidated assets increased 103% to $16.2 million from $8.0 million in Q2 2024
- Shareholders' equity rose to $9.5 million from $8.0 million year-over-year
- Diluted loss per share improved to $(0.13) from $(0.42) full-year 2024 loss
- Acquired farmland in Taiwan valued at approximately $3.3 million for R&D and GMP expansion
- Received $350,000 in licensing revenue from AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation in July 2025

## SEC filing metadata
- accession: 0001213900-25-076018
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025076018/0001213900-25-076018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025076018/ea0253086-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-076018
- JSON: https://secwatch.observer/filing/0001213900-25-076018.json
- Plain text: https://secwatch.observer/filing/0001213900-25-076018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.